Kevin Judice, DICE Therapeutics CEO
October 11, 2022 11:06 AM EDTUpdated October 12, 09:21 AM
R&D

Up­dat­ed: DICE rolls on as lead oral IL-17 can­di­date meets proof-of-con­cept in PhI tri­al, send­ing shares high­er

Paul Schloesser

Associate Editor

DICE Ther­a­peu­tics is now mov­ing for­ward on the next stage of clin­i­cal de­vel­op­ment for its IL-17 can­di­date, on the heels of tout­ing a Phase I …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times